Company / Net Income
Mineralys Therapeutics, Inc. Net Income History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$177.8M
FY2024
5-year range
-$177.8M / -$29.8M
FY2022-FY2024
Trend
-147.3%
vs FY2023
Sector context
#148 of 216
Health Care
What the data says
At -$178M, Mineralys Therapeutics, Inc.'s net income ranks #148 of 216 in the Health Care sector. Declined from -$30M to -$178M over the past 2 years.
Based on SEC 10-K filings.
-$178M in FY2024.
Declined from -$30M to -$178M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#148 of 216 in Health CareTop 69% of 216This company -$177.8M Sector average $454.3M
▼
-139.1% below sector average
Key checks
Key Insights
- In FY2024, net income decreased 147.3% year-over-year.
- Ranks #148 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$177.8M | -147.3% |
| FY2023 | -$71.9M | -141.3% |
| FY2022 | -$29.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026